New study aims to outsmart recurring c. diff infections
NCT ID NCT07328971
First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study compares two treatments to prevent Clostridioides difficile (C. diff) infection from returning. About 500 adults with a first or second C. diff episode will receive either a vancomycin taper or a 10-day course of fidaxomicin. The goal is to see if the vancomycin taper works just as well at preventing recurrence within 56 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLOSTRIDIA DIFFICILE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
McGill University Health Centre
RECRUITINGMontreal, Quebec, H4A0B1, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.